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computed tomography (CT); consequently, LN levels are 
delineated according to vessels and muscular boundaries. 
Magnetic resonance imaging (MRI) allows high resolution and 
high contrast images for explicit LN visualization in supine RT 
position. The purpose of the study was to assess effects of 
sentinel-node-biopsy (SNB) on MRI detection rate and on 
patient endurance, and relate MRI detection rate to CT. 
 
Material and Methods: Currently, 8 of in total 25 female 
early-stage breast-cancer patients (cT1-3, N0) have been 
enrolled, scheduled for SNB and breast-conserving surgery 
(BCS). Additional to standard postoperative CT for RT 
planning, all patients were scanned on 1.5 T MRI, before and 
after BCS. CT and MRI were performed in supine RT position, 
with both arms abducted and supported. MRI comprised two 
T1-weighted (T1w) spoiled gradient echo techniques, two 
T2w fast spin echo methods, and diffusion-weighted MRI, all 
covering the axillary and periclavicular areas using posterior 
and anterior 16-array coils. MRI acquisition was limited to 20 
minutes per session. Patient endurance to undergo MRI was 
monitored qualitatively. A radiation oncologist delineated LN 
levels on both MRI and CT (levels I-IV, interpectoral) 
according to ESTRO contouring guidelines. By inspection of all 
MRI scans acquired in one session, individual LNs were 
delineated. The detection rate, i.e. number of LNs 
identified, was determined for CT and for each MRI session. 
The pre- and postoperative MRI detection rates were 
compared to assess influence of SNB, and also compared to 
CT. For each LN, the corresponding LN level was denoted. 
 
Results: The number of LNs on postoperative MRI exactly 
matched the preoperative number for all 8 patients (range: 
19 – 42), when adding the excised SNs. All SNs were 
retrospectively identified in level I on preoperative MRI. In 7 
out of 8 patients, spatial correspondence of all other LNs 
between MRI sessions was established. In one patient, a post-
SNB seroma was visible, but detection number was 
unaffected. The majority of LNs were located in the LN 
levels, while up to 7 were found outside (up to 6 mm). LN 
detection on CT (7 – 21 LNs) was much lower than MRI. 





Conclusion: MRI after SNB is able to identify the exact 
numbers of LNs as found on pre-SNB MRI. CT detection rate is 
much lower than MRI. SNB does not affect patient endurance. 
All excised SNs were identified on preoperative MRI. Some 
LNs were located just outside the LN levels. MRI in RT 
planning may lead to better target definition compared to 
CT. In future studies, we will study personalized RT using MRI 
guidance, possibly leading to reduced target volume. Based 
on current patient inclusion rate, updated results on all 25 
patients are expected soon. 
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Purpose or Objective: 
Background: Partial breast irradiation (PBI) is an attractive 
treatment option for well selected women undergoing breast 
conserving therapy for early stage breast cancer. In properly 
selected women, outcomes following PBI are comparable to 
conventional whole breast radiation. The CyberKnife linear 
accelerator may offer meaningful technical improvements to 
existing PBI techniques. We report our experience with 
CyberKnife stereotactic accelerated partial breast irradiation 
(CK-SAPBI).  
 
Material and Methods: Between 11/2008 and 09/2015, CK-
SAPBI was attempted on 21 patients with early stage breast 
cancer. Four to six gold fiducials were implanted around the 
lumpectomy cavity prior to treatment. Fiducials were tracked 
in real-time using the CK Synchrony tracking system. Prior to 
2014, the clinical target volume (CTV) was defined on 
contrast enhanced CT scans using surgical clips and the 
obvious post-operative cavity. A 5 mm uniform expansion was 
added to generate the planning treatment volume (PTV). 
Starting in 2014, the CTV was defined on contrast enhanced 
CT scans as the lumpectomy cavity plus a 10 mm uniform 
expansion confined to the breast tissue. A 3-5 mm uniform 
expansion was added to generate the PTV. All patients 
received 30 Gy in five fractions delivered to the PTV. 
Dosimetry was assessed per institutional protocol, the 
National Surgical Adjuvant Breast and Bowel Project B-39 
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guidelines, and TG-101. Cosmesis was assessed using the 
Harvard Breast Cosmesis Scale.  
 
Results: Twenty patients were treated successfully. At a 
median follow-up of 18 months (1-78), all patients remain 
locally controlled (100%) and no significant adverse events 
have occurred. All patients continue to experience good-
excellent cosmetic outcomes. At least 3 fiducials were 
tracked in 85% of cases. Fiducial tracking was not successful 
in one patient. The mean number of beams delivered was 145 
(77-196). The mean treated PTV30Gy was 74 cm3 (15-142 
cm3) with a mean prescription isodose line of 82% (75-86%). 
99% of the PTV30Gy received the prescription dose (95-100%) 
with a mean maximum dose of 36 Gy (34.5-40Gy). The mean 
ipsilateral breast V30Gy and V15Gy were 12% (3-26%) and 30% 
respectively (8-58%) sparing significant amounts of normal 
breast tissue. Patient tolerance was excellent and acute 
toxicity was rarely observed. 2 patients experienced grade 1 
localized dermatitis at the initial 4 week follow-up visit. 
 
Conclusions: CyberKnife stereotactic accelerated partial 
breast irradiation is a suitable radiotherapy technique for the 
delivery of partial breast irradiation. The CK platform 
produces highly conformal treatments with excellent normal 
tissue sparing and offers improvements over existing PBI 
techniques. Our experience indicates that CK-SAPBI delivered 
in five fractions is well tolerated with excellent short term 
local control and breast cosmesis. Longer follow-up is needed 
for assessment of late toxicity and oncologic outcomes.  
 
EP-1163  
Selection of patients with left breast cancer for Deep-
Inspiration Breath-Hold Radiotherapy Technique 
B. Czeremszynska
1Independent Public Health Care Facility of the Ministry of 
the Interior, Radiotherapy Department, Olsztyn, Poland 
1, S. Drozda2, M. Górzyński1, L. Kępka1 
2University of Warmia and Mazury, Faculty of Mathematics 
and Computer Science, Olsztyn, Poland 
 
Purpose or Objective: The voluntary deep-inspiration 
breath-hold radiotherapy technique (DIBHRT) in the 
treatment of left breast cancer has the ability to reduce 
doses to heart left anterior descending coronary artery (LAD) 
and lung. Before introduction of DIBHRT into routine clinical 
practice, we conducted a prospective study to assess the 
extent of dosimetric benefit of this technique in order to 
select a group of patients for whom this technique should be 
routinely applied 
 
Material and Methods: Thirty one consecutive patients 
qualified for whole breast irradiation (WBI) with tangential 
fields following breast conserving surgery for left-sided early 
breast cancer were included. All patients underwent breath-
hold training, free-breathing (FB) and DIBH planning-CT. 
Separate radiotherapy treatment plans for WBI in total dose 
of 39.9Gy in 15 fraction were prepared based on both 
planning-CT. Doses like mean heart, heart V20Gy, maximum 
LAD, left lung V20Gy were calculated for each plan and the 
difference of respective values (delta) for FB and DIBH were 
calculated. If relative improvement of at least 20%for any 
evaluated dosimetric parameter were found for DIBH plan 
without significant worsening of other measures, this plan 
was selected for treatment. Daily tree-dimensional surface 
imaging (VisionRT) and weekly electronic portal imaging were 
performed. The data distribution were assessed using chi² 
test, correlations were analyzed using the Pearson test. 
Furthermore, receiver operating characteristic (ROC) analysis 
was performed. 
 
Results: In 30 of 31 patents a reduction at least 20% in one or 
more evaluated parameters (i.e.mean heart, heart V20Gy, 
maximum LAD and left lung V20Gy in 29, 29, 26, and 7 
patents respectively)was achieved. The relative worsening of 
left lung V20Gy was found for in 10 and cases and of 
maximum LAD in 2 cases. Eventually 25 patients were 
qualified to DIBHRT. Mean delta(Gy) were:mean heart 1.51 
(range:0.06-6.45),heart V20Gy:3.0 (range:0.0-6.59),maximum 
LAD:18.5(range:-3.29-36.68), left lung V20Gy:1.7(range:-
2.71-8.7). Correlations between delta values of mean heart, 
maximum LAD, heart V20Gy with length of cardiac contact 
distance (CCD) (p< 0.05, AUC>0,6) and maximum LAD, heart 
V20Gy with Body Mass Index (BMI)(p<0.05;AUC>0.6) were 
found. ROC analysis showed that a 2.5 cm of CCD is a 
threshold for reduction at least 20% in one or more 
parameters. For BMI no specific threshold for predefined 
improvement of any dosimetric parameter was identified, 
which means that despite correlation of dosimetric cardiac 
benefit with higher BMI, some patients with low BMI may also 
have cardiac doses reduced with DIBHRT. 
 
Conclusion: In our center we have prospectively confirmed 
an ability of DIBHRT for heart and LAD but not for lung-
sparing. We are going to use this technique routinely for left-
sided breast cancer patients with CCD above 2.5 cm 
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Purpose or Objective: Post-mastectomy radiation therapy 
(PMRT) is standard care for breast cancer patients with high 
risk for locoregional recurrence after mastectomy. The 
indication for PMRT in patients with 1 to 3 positive nodes has 
been in discussion. We reported that patients concomitantly 
with 1 to 3 positive nodes and extensive lymphatic invasion, 
who had not been treated with PMRT from 1990 to 2000, had 
13.1% (12/92) of locoregional recurrence rate. Since then we 
have performed PMRT for patients with 1 to 3 positive nodes 
and extensive lymphatic invasion. 
To investigate the effectiveness of PMRT for patients with 1 
to 3 positive nodes and extensive lymphatic invasion. 
 
Material and Methods: Between 2005 and 2013, 639 patients 
were treated with PMRT and 277 patients of those have not 
been without neoadjuvant chemotherapy until the lymph 
node dissection. Among these patients, 81 were diagnosed 
with 1 to 3 positive nodes pathologically, 65 were with 1 to 3 
positive nodes and extensive lymphatic invasion. The 3-D 
conformal RT, using the partial wide tangent technique to 
the chest wall, internal mammary lymph nodes and supra-
clavicular nodes, was applied for all patients, delivering 50 
Gy in 25 fractionation over 5 weeks. In the patients with 
positive surgical margin, 10 Gy of electron boost to the tumor 
bed was added. We retrospectively reviewed and compared 
locoregional recurrence rates of 65 patients with 1 to 3 
positive nodes and extensive lymphatic invasion treated with 
PMRT and that of 92 patients without PMRT. 
 
Results: Baseline patient characteristics; the median age of 
these patients was 47 years old (range; 34-76). Survivals; the 
median duration of overall survival was 114 months (30 to 
121 months), the five-year survival rate is 97%, and the 
median progression-free survival time after PMRT was 93 
months (7.0 to 110 months). Of the 65 patients in the current 
analysis, 58 patients (89%) were alive and free of cancer. 
Initial failure patterns; the locoregional recurrence was 
observed in 3 patients (4.6%), classifying into 1 chest wall, 1 
regional lymph node, and 1 both. All patients with 
locoregional recurrence were developed the distant 
metastases then after. As toxicity; radiation induced 
pneumonitis graded 1 was observed in 9 patients, nor been 
graded 2 or more observed. Acute radiation induced 
dermatitis was observed almost all patients at least grade 1, 
grade3 was observed in 9 patients. One patient denied 
continuing PMRT at dose of 46Gy, 7 months later her chest 
wall recurrence was observed. 
 
